Mechanism by which the Grp94 molecular chaperone folds insulin-like growth factors
Mechanism by which the Grp94 molecular chaperone folds insulin-like growth factors
批准号:
10246944
负责人:
Timothy Oliver Street
金额:
$39.83万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-01 至 2024-06-30
关键词:
ATP HydrolysisAntineoplastic AgentsAreaAttentionBehaviorBinding SitesBiologicalBiotechnologyCellsClientClinical TrialsCollaborationsComplexCytosolDetectionDiseaseDissociationDisulfidesDrug TargetingEndoplasmic ReticulumEnvironmentFamilyGoalsGolgi ApparatusGrowth FactorHealthHeat-Shock Proteins 70HormonesHumanIGF1 geneIGF2 geneIn VitroIndividualInsulinLinkMalignant NeoplasmsMeasurementMitochondriaMolecular ChaperonesMolecular ConformationMolecular StructureNon-Insulin-Dependent Diabetes MellitusOncogenicPathologyPeptidesProcessProductionProinsulinPropertyProteinsRecording of previous eventsResearchRoleSomatomedinsStructure of beta Cell of isletSystemTestingTimeUniversitiesWorkYeastsanalogimprovedinhibitor/antagonistinnovationinsulin secretionmembernovelpeptide hormoneprotein foldingsingle-molecule FRET
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The endoplasmic reticulum (ER) chaperone Grp94 is required for the correct folding and secretion of
insulin-like growth factors (IGF), but the underlying mechanism is not understood. Our goal is to discover how
Grp94 assists the folding of IGF proteins. Grp94 is a member of the Hsp90 chaperone family, which require ATP-
driven conformational cycling to chaperone their “client proteins”. Many oncogenic proteins depend on Hsp90
for their function. As a result, ATP-competitive inhibitors of Hsp90 have been extensively investigated as anti-
cancer drugs. Although cytosolic Hsp90s were the first intended targets of inhibitors in clinical trials, Grp94 is
receiving increasing attention as a drug target. Grp94 can receive clients from BiP, the Hsp70-family chaperone
in the ER. Through a chance discovery, we have found that the combination of BiP and Hsp90 inhibitors locks
Grp94 in a novel conformation, a state apparently poised for client transfer from BiP to Grp94. Client transfer
from BiP to Grp94 requires two sequential steps: handover of the client from BiP to Grp94, followed by BiP
dissociation from the ternary complex. Our first hypothesis is that Hsp90 inhibitors block both steps: Hsp90
inhibitors stall Grp94 and BiP in a client transfer state because ATP-dependent conformational changes
of Grp94 are required to handover the client from BiP and then displace BiP from Grp94. We will test this
hypothesis with IGF2, as we have discovered that this Grp94 client also has a well-defined BiP binding site.
Aim1: Determine whether ATP-dependent conformational changes of Grp94 cause BiP to handover a bound
client protein, and whether Hsp90 inhibitors disrupt this client-transfer function. Aim2: Determine whether ATP-
dependent conformational changes of Grp94 are required to actively displace BiP from Grp94. Aims 1&2 will test
a unified mechanism that can explain how Hsp90 inhibitors disrupt Grp94 function, but does not explain what
essential chaperoning function is provided by BiP and Grp94 for IGF proteins. We have discovered that IGF2
forms dynamic oligomers. Similar to other peptide hormones that are known to oligomerize, this self-association
may enable IGF2 to be effectively concentrated and packaged prior to its export to the Golgi. Despite a plausible
biological role for IGF2 oligomerization, we have also observed that IGF2 can transition from dynamic reversible
oligomers to irreversible aggregates. Thus, our second hypothesis is that the essential chaperoning function
of BiP and Grp94 is to maintain a dynamic oligomerization state of IGF2. This idea is tested in Aim3:
Determine the influence of Grp94 and BiP on the oligomerization properties of ProIGF2.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanism by which the Grp94 molecular chaperone folds insulin-like growth factors
-
批准号:10655479
-
项目类别:
-
资助金额:$39.79万
-
财政年份:2015
-
负责人:Timothy Oliver Street
-
依托单位:
Mechanism by which the Grp94 molecular chaperone folds insulin-like growth factors
-
批准号:9282446
-
项目类别:
-
资助金额:$31.94万
-
财政年份:2015
-
负责人:Timothy Oliver Street
-
依托单位:
Mechanism by which the Grp94 molecular chaperone folds insulin-like growth factors
-
批准号:10437917
-
项目类别:
-
资助金额:$39.81万
-
财政年份:2015
-
负责人:Timothy Oliver Street
-
依托单位:
Mechanism by which the Grp94 molecular chaperone folds insulin-like growth factors
-
批准号:10612146
-
项目类别:
-
资助金额:$3.74万
-
财政年份:2015
-
负责人:Timothy Oliver Street
-
依托单位:
Mechanism by which the Grp94 molecular chaperone folds insulin-like growth factors
-
批准号:8937336
-
项目类别:
-
资助金额:$31.51万
-
财政年份:2015
-
负责人:Timothy Oliver Street
-
依托单位:
海外基金